A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

NCT05024032 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication tirzepatide in Chinese adults who have obesity or are overweight but do not have type 2 diabetes to see how it affects body weight.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 210 people

Who can join Ages 18+ · all sexes

Timeline Started 2021-09 · est. completion 2022-12

Where 29 sites · China

What this study is testing ClinicalTrials.gov NCT05024032 ↗

Description as written by the study sponsor.

This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight. The main purpose is to learn more about how tirzepatide affects body weight.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Mean Percent Change From Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight, Metabolism and Nutrition Disorder
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05024032 ↗